Workflow
CAINA TECHNOLOGY CO.(301122)
icon
Search documents
采纳股份(301122) - 2022年2月8日-2月10日投资者关系活动记录表
2022-11-21 05:32
证券代码:301122 证券简称:采纳股份 编号:2022-01 采纳科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | ■现场参观 □其他 (请文字说明其他活动内容) | | | | 华创证券:郑辰、李婵娟 人保资产:蔡春根 | | | | 博时基金:张弘 | 天风证券:杨松、张雪 | | | 招商证券:孙炜、许菲菲 | 汇添富基金:张韡、谢杰 | | | | 中泰证券:彭婷 宝盈基金:姚艺、刘迪 | | 参与单位名称及 | 中欧基金:王建礼、任逸哲 大成基金:陈泉龙 | | | 人员姓名 | 景顺长城:姜雪婷、詹成 | 交银施罗德:朱亦宁 | | | 兴全基金:隋毅 东方红 ...
采纳股份(301122) - 2022年8月投资者关系活动记录表
2022-11-11 05:54
1 / 6 证券代码:301122 证券简称:采纳股份 采纳科技股份有限公司 投资者关系活动记录表 编号:2022-03 | --- | --- | --- | --- | |---------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------| | 投资者关系活动 类别 | ■特定对象调研 | ■分析师会议 □媒体采访 \n□业绩说明会 □新闻发布会 \n■现场参观 ■其他(电话会议) | □路演活动 | | 参与单位名称及 | 86 家机构参与,详见附件清单。 | | | | 人员姓名 | | | | | 时间 | 2022 年 8 月 25 日-8 | 月 31 日 | | | 地点 | 公司会议室 | | | | 上市公 ...
采纳股份(301122) - 2022 Q3 - 季度财报
2022-10-25 16:00
Revenue and Profit - Revenue for Q3 2022 was CNY 103,230,278.41, a decrease of 4.53% compared to the same period last year, while year-to-date revenue increased by 22.42% to CNY 377,380,539.19[5] - Net profit attributable to shareholders for Q3 2022 was CNY 34,478,195.55, an increase of 16.92% year-over-year, and year-to-date net profit rose by 47.79% to CNY 134,145,786.51[5] - Basic earnings per share for Q3 2022 was CNY 0.37, down 11.90% from the previous year, while year-to-date basic earnings per share increased by 13.95% to CNY 1.47[5] - Total operating revenue for Q3 2022 reached ¥377,380,539.19, an increase of 22.4% compared to ¥308,269,176.69 in the same period last year[18] - Net profit for Q3 2022 was ¥134,145,786.51, representing a significant increase of 47.6% from ¥90,767,716.96 in Q3 2021[19] - The net profit attributable to the parent company for Q3 2022 was ¥134,145,786.51, an increase from ¥90,767,716.96 in Q3 2021, representing a growth of approximately 47.7%[20] - The basic and diluted earnings per share for Q3 2022 were both ¥1.47, compared to ¥1.29 in Q3 2021, reflecting an increase of 13.9%[20] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 1,800,360,272.88, representing a 193.88% increase compared to the end of the previous year[5] - The company's total assets as of September 30, 2022, were ¥1,800,360,272.88, compared to ¥612,622,396.12 at the beginning of the year, indicating a growth of 194.2%[16] - Current assets totaled ¥1,426,508,493.23, a substantial increase from ¥322,752,195.47 at the start of the year, marking a growth of 342.5%[16] - The total liabilities decreased to ¥91,739,897.29 from ¥102,497,916.74, a reduction of 10.5%[16] - The equity attributable to shareholders increased to ¥1,708,620,375.59 from ¥510,124,479.38, representing a growth of 234.5%[16] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 102,556,801.86, an increase of 10.49%[5] - The total cash inflow from operating activities for Q3 2022 was ¥399,389,868.18, up from ¥345,396,696.34 in the same period last year, indicating a growth of about 15.6%[22] - The net cash flow from operating activities for Q3 2022 was ¥102,556,801.86, compared to ¥92,817,214.41 in Q3 2021, showing an increase of approximately 10.4%[22] - The total cash inflow from investment activities was ¥953,409,088.42 in Q3 2022, significantly higher than ¥8,086,049.55 in Q3 2021[22] - The net cash flow from investment activities for Q3 2022 was -¥890,775,659.18, compared to -¥60,565,672.02 in Q3 2021, indicating a larger outflow[22] - The net cash flow from financing activities for Q3 2022 was ¥1,059,027,082.65, a significant increase from -¥21,250,984.49 in Q3 2021[23] - The cash and cash equivalents at the end of Q3 2022 totaled ¥420,822,262.97, compared to ¥137,550,033.49 at the end of Q3 2021, reflecting a substantial increase of approximately 205.5%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,852[10] - The largest shareholder, Lu Jun, holds 28.29% of the shares, totaling 26,600,000 shares[10] - The second-largest shareholder, Lu Weiwei, owns 16.16% of the shares, amounting to 15,200,000 shares[10] - The top ten shareholders collectively hold a significant portion of the company's equity, with the largest three shareholders alone accounting for over 52%[10] - The company has a total of 71,739,481 restricted shares, with 1,213,159 shares released during the reporting period[13] - The company has no preferred shareholders or related party transactions disclosed in the report[12] - The company plans to maintain its current shareholder structure without any immediate changes in the financing or equity distribution[11] Expenses and Costs - The company experienced a 68.67% decrease in selling expenses, primarily due to the adjustment of transportation costs to operating costs under new revenue standards[8] - Total operating costs amounted to ¥234,345,989.54, up from ¥206,412,615.30, reflecting a year-over-year increase of 13.5%[19] - Research and development expenses for Q3 2022 were ¥14,871,258.25, compared to ¥13,206,254.81 in the previous year, indicating an increase of 12.6%[19] Future Outlook - The report indicates that there are no new product launches or technological advancements mentioned for the upcoming quarter[12] - The company has not disclosed any market expansion or acquisition strategies in the current report[12] - There are no significant changes in the financial performance metrics provided in the report[12]
采纳股份(301122) - 2022 Q2 - 季度财报
2022-08-24 16:00
Financial Performance - The company's operating revenue for the first half of 2022 was RMB 274,150,260.78, representing a 36.98% increase compared to RMB 200,145,591.84 in the same period last year[22]. - Net profit attributable to shareholders was RMB 99,667,590.96, a 62.64% increase from RMB 61,279,502.57 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was RMB 90,941,909.47, up 59.06% from RMB 57,176,094.08 in the previous year[22]. - The net cash flow from operating activities was RMB 103,569,213.39, an increase of 34.16% compared to RMB 77,196,575.53 in the same period last year[22]. - Basic and diluted earnings per share were both RMB 1.11, reflecting a 27.59% increase from RMB 0.87 in the previous year[22]. - Total assets at the end of the reporting period reached RMB 1,769,695,310.03, a significant increase of 188.87% from RMB 612,622,396.12 at the end of the previous year[22]. - Net assets attributable to shareholders increased by 228.18% to RMB 1,674,142,180.04 from RMB 510,124,479.38 at the end of the previous year[22]. - The company's operating costs rose to ¥155,044,588.39, reflecting a 45.45% increase, primarily driven by the expanded sales scale[69]. - The total profit for the first half of 2022 was ¥116,172,431.60, compared to ¥71,391,504.22 in the first half of 2021, marking a 62.8% increase[178]. Market Position and Strategy - The company is focused on expanding its market presence and developing new products and technologies, although specific details were not disclosed in the report[6]. - The company operates in a growing market for medical devices, particularly in the injection and puncture product segment, which is expected to see stable demand growth driven by population and income factors[36]. - The company aims to strengthen its market position in high-value products such as safety insulin pen needles and pre-filled syringes[45]. - The company is actively involved in setting industry standards, contributing to the development of guidelines for medical devices in China, which enhances its reputation and influence in the market[31]. - The company has established a stable customer base, providing products to globally recognized large companies, ensuring continuous order growth[66]. - The company plans to enhance its R&D center and focus on developing core technologies to ensure its leading position in the industry[90]. Research and Development - Research and development investment increased by 8.16% to ¥9,786,543.48, indicating a commitment to innovation[69]. - The company is investing 200 million yuan in research and development for new technologies aimed at enhancing user experience[114]. - The company has established a research and development system focused on market needs, with dedicated technology research centers for veterinary and safety injection devices[53]. - The company is focusing on research and development of new technologies to maintain competitive advantage in the market[192]. Quality Control and Compliance - The company has achieved compliance with international quality management standards, including ISO13485 and ISO11135, ensuring high product quality and safety[30]. - The company has established a quality assurance system compliant with ISO13485 and FDA standards, enhancing product quality control[39]. - The company emphasizes customer care and regulatory compliance as part of its quality assurance strategy[56]. - The company has implemented a comprehensive quality management system, certified by ISO13485 and MDSAP, ensuring compliance with international standards[56]. Shareholder and Financial Management - The company plans to repurchase shares using its own funds, with the repurchase price not exceeding the net asset value per share at the end of the previous fiscal year[116]. - The total amount used for share repurchase will not exceed 50% of the net profit attributable to shareholders of the parent company at the end of the previous fiscal year[116]. - The company has committed to enhancing management levels and improving capital efficiency to boost operational efficiency and profitability[118]. - The company will prioritize cash dividends when profits and cash flow allow, with a focus on maintaining a positive outlook for future development[119]. - The company has committed to returning shareholder value through sustainable development and operational efficiency improvements[118]. Community and Environmental Responsibility - The company donated a total of RMB 303,000 to the Jiangyin Charity Association for local pandemic prevention efforts[110]. - The company has committed to environmental protection and sustainable development, complying with national and local laws[109]. - The company has implemented measures to reduce carbon emissions, although specific details were not disclosed[104]. - The company emphasizes a "people-oriented" development philosophy, providing employees with social insurance and other benefits[107]. Future Outlook - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30%[114]. - New product launches are expected to contribute an additional 500 million yuan in revenue by the end of 2022[114]. - Market expansion plans include entering three new international markets by Q4 2022, targeting a 10% market share in each[114]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[200].
采纳股份(301122) - 2022 Q1 - 季度财报
2022-04-25 16:00
Financial Performance - The company's revenue for Q1 2022 was CNY 141,589,832.60, representing a 39.46% increase compared to CNY 101,524,120.08 in the same period last year[3] - Net profit attributable to shareholders was CNY 39,324,380.01, a 6.40% increase from CNY 36,958,321.53 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 141,589,832.60, an increase of 39.5% compared to CNY 101,524,120.08 in the same period last year[22] - Net profit for Q1 2022 reached CNY 39,324,380.01, representing a 6.0% increase from CNY 36,958,321.53 in Q1 2021[24] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.46, down from CNY 0.52 in the previous year[25] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 724,544.89, a decline of 102.43% compared to CNY 29,778,559.16 in the previous year[3] - Cash flow from operating activities showed a net outflow of CNY 724,544.89, compared to a net inflow of CNY 29,778,559.16 in the same period last year[27] - The company reported a total cash inflow from operating activities of CNY 121,843,427.27, compared to CNY 104,881,521.91 in the previous year[27] - The ending balance of cash and cash equivalents reached 802,495,998.92 CNY, a substantial increase from the beginning balance[28] - The company experienced a foreign exchange impact of -310,072.85 CNY on cash and cash equivalents[28] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 1,737,250,512.81, an increase of 183.58% from CNY 612,622,396.12 at the end of the previous year[3] - Total liabilities decreased to CNY 84,981,847.89 from CNY 102,497,916.74 year-over-year[21] - The company reported a total of CNY 307,136,096.01 in non-current assets, up from CNY 289,870,200.65, indicating a growth of approximately 6%[20] - Total current liabilities decreased from CNY 65,025,371.10 to CNY 45,454,917.72, a reduction of about 30%[20] Shareholder Equity - The company's equity attributable to shareholders increased by 223.90% to CNY 1,652,268,664.92 from CNY 510,124,479.38[3] - Total equity attributable to shareholders increased significantly to CNY 1,652,268,664.92 from CNY 510,124,479.38 in the previous year[21] Investment Activities - The company’s investment activities generated a net cash outflow of CNY 427,404,403.50, a 1420.15% increase compared to the previous year[13] - The net cash flow from investment activities was -427,404,403.50 CNY, indicating a significant outflow compared to the previous period[28] - Cash outflow for investment activities totaled 527,604,403.50 CNY, highlighting significant investments made during the quarter[28] Operating Costs and Expenses - Total operating costs for Q1 2022 were CNY 93,817,830.80, up 62.1% from CNY 57,870,086.31 in Q1 2021[22] - The company’s management expenses increased by 96.77% to CNY 7,548,693.07, primarily due to costs associated with the IPO[11] - Research and development expenses for Q1 2022 were CNY 4,889,125.57, compared to CNY 4,093,637.63 in Q1 2021, indicating a focus on innovation[22] Share Capital and IPO - The company completed its initial public offering, resulting in a 33.33% increase in share capital to CNY 94,035,122.00[9] - The company reported a significant increase in cash and cash equivalents, rising by 520.13% to CNY 802,495,998.92 due to funds raised from the IPO[8] Other Notable Information - The company has not disclosed any new product launches or technological developments during this quarter[18] - There are no significant mergers or acquisitions reported in this quarter[18] - The company has not provided specific future guidance or market expansion strategies in the current report[18] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder owning 6.38%[17] - The company did not undergo an audit for the first quarter report, which may affect the perception of financial reliability[29] - The cash flow from operating activities was not detailed in the provided data, suggesting a need for further analysis[28]
采纳股份(301122) - 2021 Q4 - 年度财报
2022-03-10 16:00
Financial Performance - The company's operating revenue for 2021 was approximately ¥442.05 million, a decrease of 12.47% compared to ¥505.01 million in 2020[17]. - The net profit attributable to shareholders for 2021 was approximately ¥130.68 million, down 4.63% from ¥137.03 million in 2020[17]. - The net profit after deducting non-recurring gains and losses increased by 122.21% to approximately ¥125.37 million from ¥56.42 million in 2020[17]. - The total assets at the end of 2021 reached approximately ¥612.62 million, an increase of 28.77% from ¥475.75 million at the end of 2020[17]. - The net assets attributable to shareholders increased by 34.44% to approximately ¥510.12 million from ¥379.44 million in 2020[17]. - The basic earnings per share for 2021 was ¥1.85, a decrease of 9.76% compared to ¥2.05 in 2020[17]. - The weighted average return on equity for 2021 was 29.38%, down 21.03% from 50.41% in 2020[17]. - Total revenue for 2021 was ¥442,051,932.24, a decrease of 12.47% compared to ¥505,006,042.95 in 2020[73]. - Revenue from medical products decreased by 37.55% to ¥211,776,347.04, while revenue from veterinary products increased by 53.78% to ¥155,443,130.39[73]. - The company’s export revenue reached ¥397,990,843.70, accounting for 90.03% of total revenue, with a year-on-year increase of 44.26%[74]. Market Position and Strategy - The company operates in the specialized equipment manufacturing industry, focusing on medical and veterinary instruments, with a strong emphasis on innovation and core competitiveness[28]. - The company is a leading manufacturer of medical and veterinary injection devices in China, with a market share of 1st in the domestic veterinary injection market according to FROST & SULLIVAN's 2019 report[36]. - The company has a diverse product line including disposable sterile syringes, anesthesia syringes, and high-value products like safety insulin syringes, aiming to enhance its market position in high-safety and high-value product areas[35]. - The company’s strategy includes continuous innovation in injection and puncture products to meet clinical and home healthcare market needs[32]. - The company is focusing on developing high-end, intelligent, and safe injection products to meet increasing market demand driven by aging populations and advancements in medical technology[114]. Research and Development - The company reported a total R&D investment of ¥18,439,987.91 in 2021, representing 4.17% of its operating revenue, an increase from 3.70% in 2020[90]. - The number of R&D personnel increased by 23.88% from 67 in 2020 to 83 in 2021, with a notable rise in the number of personnel aged under 30 by 40%[90]. - The company is developing several new products, including a needle-free connector and a pre-filled catheter flushing device, aimed at enhancing product lines and competitiveness[88]. - The company has obtained 21 FDA 510K registrations and 28 CE certifications for its medical device products as of the end of the reporting period[90]. - The company aims to improve its R&D capabilities and further advance brand construction to consolidate and increase market share[198]. Operational Efficiency - The production model is based on customer orders, adopting a "sales-driven production" approach to ensure quality and efficiency[50]. - The company has optimized its production processes to enhance automation and improve production efficiency[51]. - The company aims to improve production efficiency by over 50% through the automation of the veterinary syringe production process[88]. - The company has established a comprehensive service offering that includes product design, material selection, and mass production, catering to global clients like Neogen and Thermo Fisher[38]. Risk Management - The company has identified potential risks in its operations and outlined corresponding countermeasures in its future outlook section[5]. - The company recognizes the risk of talent loss in the technology sector and is implementing incentive policies to retain key technical personnel[117]. - The company is preparing for potential impacts from U.S.-China trade tensions, which could affect its export business and pricing strategies[111]. - The company is actively working to reduce reliance on major clients by expanding its product offerings and cultivating new customer relationships[113]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[124]. - The supervisory board is composed of 3 members, including 1 employee representative, fulfilling legal requirements for governance[125]. - The company maintains an independent operational structure, ensuring no adverse effects from the controlling shareholder on governance and independence[127]. - The company emphasizes transparency in information disclosure, adhering to legal regulations and ensuring timely and accurate information dissemination[128]. Social Responsibility - The company donated RMB 200,000 to the "Rural Revitalization Common Prosperity Fund" to fulfill its social responsibility[186]. - The company is committed to fulfilling its social responsibilities and actively participating in charitable activities during the reporting period[187]. - The company has established a fund aimed at enhancing village-level collective economies and improving living environments in economically weaker rural areas[187]. Shareholder Returns - The company plans to distribute a cash dividend of 3.50 CNY per 10 shares, totaling 32,912,292.70 CNY, based on a total share capital of 94,035,122 shares[165]. - The cash dividend represents 100% of the total distributable profit of 151,754,753.17 CNY for the year[165]. - The company has committed to a cash dividend distribution of at least 10% of the annual distributable profit when conditions are met[200]. - The company will conduct profit distribution once a year after the annual general meeting approval[200]. Employee Management - The total number of employees at the end of the reporting period was 794, with 345 in the parent company and 449 in major subsidiaries[160]. - The company has implemented a training mechanism to enhance employee skills and foster a strong corporate culture[163]. - The company plans to attract high-level technical and management talents through competitive compensation and training programs over the next three years[163].